Designing vaccines to prevent breast cancer recurrence or invasive disease.
作者信息
Stanton Sasha E, Disis Mary L
机构信息
Tumor Vaccine Group, Center for Translational Medicine in Women's Health, 850 Republican Street, 2nd Floor, Box 358050, University of Washington, Seattle, WA 98195-8050, USA.
出版信息
Immunotherapy. 2015;7(2):69-72. doi: 10.2217/imt.15.5.
Abstract
摘要
相似文献
1
Designing vaccines to prevent breast cancer recurrence or invasive disease.设计预防乳腺癌复发或侵袭性疾病的疫苗。
Immunotherapy. 2015;7(2):69-72. doi: 10.2217/imt.15.5.
2
Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy.癌症疫苗：肿瘤负荷在决定疫苗疗效方面的作用。
J Clin Oncol. 2005 Oct 20;23(30):7397-8. doi: 10.1200/JCO.2005.07.020. Epub 2005 Sep 26.
3
Vaccine studies demonstrate promise of immunotherapy to treat breast cancer and prevent recurrence.疫苗研究表明免疫疗法在治疗乳腺癌和预防复发方面具有前景。
Oncology (Williston Park). 2000 Oct;14(10):1415-6.
4
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.一种HER2/neu（E75）疫苗预防高危乳腺癌患者复发的临床试验结果。
J Clin Oncol. 2005 Oct 20;23(30):7536-45. doi: 10.1200/JCO.2005.03.047. Epub 2005 Sep 12.
5
Breast cancer vaccines: promise for the future or pipe dream?乳腺癌疫苗：未来的希望还是白日梦？
Cancer. 2007 Oct 15;110(8):1677-86. doi: 10.1002/cncr.22978.
6
Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.用于乳腺癌和前列腺癌免疫治疗的疫苗：新进展与比较方面
In Vivo. 2002 Nov-Dec;16(6):405-15.
7
Immunizing against breast cancer: a new swing for an old sword.乳腺癌免疫接种：老药新用。
Breast. 2009 Oct;18 Suppl 3:S51-4. doi: 10.1016/S0960-9776(09)70273-5.
8
Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.疫苗接种在乳腺癌的预防和治疗中的应用，特别关注 Her-2/neu 肽疫苗。
Breast Cancer Res Treat. 2013 Feb;138(1):1-12. doi: 10.1007/s10549-013-2410-8. Epub 2013 Jan 23.
9
Breast cancer: E75-a safe and effective vaccine for the prevention of disease recurrence.乳腺癌：E75——一种预防疾病复发的安全有效的疫苗。
Nat Rev Clin Oncol. 2014 Aug;11(8):440. doi: 10.1038/nrclinonc.2014.110. Epub 2014 Jun 24.
10
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.HER2/neu（E75）疫苗预防高危乳腺癌患者复发的联合临床试验结果：美国军事癌症研究所临床试验组研究I - 01和I - 02。
Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.
引用本文的文献
1
Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells.瓜氨酸化的烯醇化酶1疫苗增强了植入小鼠三阴性乳腺癌细胞的小鼠体内的程序性死亡受体1阻断作用。
Vaccines (Basel). 2025 Jun 11;13(6):629. doi: 10.3390/vaccines13060629.
2
Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients.在乳腺癌患者血清中发现了来自小鼠乳腺癌模型的肿瘤相关自身抗体。
NPJ Breast Cancer. 2021 May 11;7(1):50. doi: 10.1038/s41523-021-00257-1.
3
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
4
Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.癌症疫苗，未来的治疗方法：重点关注 HER2 阳性乳腺癌。
Int J Mol Sci. 2021 Jan 14;22(2):779. doi: 10.3390/ijms22020779.
5
Inducing Tumor Suppressive Microenvironments through Genome Edited CD47 Syngeneic Cell Vaccination.通过基因组编辑的 CD47 同源细胞疫苗诱导肿瘤抑制性微环境。
Sci Rep. 2019 Dec 27;9(1):20057. doi: 10.1038/s41598-019-56370-6.
6
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.一项初步研究显示，在早期乳腺癌患者中，一种 9 肽乳腺癌疫苗联合聚肌胞苷酸（poly-ICLC）具有免疫原性。
J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.
7
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.在免疫检查点抑制剂时代，癌症疫苗还有空间吗？
Vaccines (Basel). 2016 Nov 3;4(4):37. doi: 10.3390/vaccines4040037.
8
The Promise of Preventive Cancer Vaccines.预防性癌症疫苗的前景
Vaccines (Basel). 2015 Jun 17;3(2):467-89. doi: 10.3390/vaccines3020467.
本文引用的文献
1
Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.从 IGFBP-2 疫苗中消除 IL-10 诱导的辅助性 T 细胞表位可确保强大的抗肿瘤活性。
Cancer Res. 2014 May 15;74(10):2710-8. doi: 10.1158/0008-5472.CAN-13-3286. Epub 2014 Apr 28.
2
A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.一种针对 neu、IGFBP-2 和 IGF-IR 的多抗原疫苗可预防乳腺疾病前期的小鼠肿瘤进展。
Cancer Prev Res (Phila). 2013 Dec;6(12):1273-82. doi: 10.1158/1940-6207.CAPR-13-0182. Epub 2013 Oct 23.
3
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.辅助性 T 细胞 I 型免疫，针对乳腺癌抗原胰岛素样生长因子-I 受体（IGF-IR），与肥胖增加有关。
Breast Cancer Res Treat. 2013 Jun;139(3):657-65. doi: 10.1007/s10549-013-2577-z. Epub 2013 Jun 8.
4
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.在一项 III 期随机辅助乳腺癌试验中，比较多西他赛联合多柔比星与多柔比星为基础的化疗在淋巴结阳性乳腺癌中的疗效，肿瘤浸润淋巴细胞的预后和预测价值：BIG 02-98。
J Clin Oncol. 2013 Mar 1;31(7):860-7. doi: 10.1200/JCO.2011.41.0902. Epub 2013 Jan 22.
5
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.浸润性乳腺癌肿瘤和导管原位癌（DCIS）的综合分子谱揭示了不同的血管和白细胞介素信号。
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2802-7. doi: 10.1073/pnas.1108781108. Epub 2011 Sep 9.
6
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.肿瘤浸润 CD8+ 淋巴细胞预测乳腺癌的临床结局。
J Clin Oncol. 2011 May 20;29(15):1949-55. doi: 10.1200/JCO.2010.30.5037. Epub 2011 Apr 11.
7
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.导管原位癌（DCIS）和早期浸润性乳腺癌中的分子多样性。
Mol Oncol. 2010 Aug;4(4):357-68. doi: 10.1016/j.molonc.2010.06.007. Epub 2010 Jun 26.
8
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.初始导管原位癌诊断后生物标志物表达与后续肿瘤风险。
J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28.
9
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.淋巴细胞和髓样细胞之间的相互作用调节抗肿瘤免疫反应。
Cancer Metastasis Rev. 2010 Jun;29(2):309-16. doi: 10.1007/s10555-010-9223-6.
10
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.胰岛素样生长因子结合蛋白-2是乳腺癌免疫调节的一个靶点。
Cancer Res. 2008 Oct 15;68(20):8400-9. doi: 10.1158/0008-5472.CAN-07-5891.
Zotero 插件